Previous Study: BCIRG 001
Next Study: BCIRG 004

Studies & Results


A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) with TAC followed by high dose chemotherapy with mitoxantrone, cyclophosphamide and vinorelbine (HDCT) with autologous peripheral stem cell transplantation and G-CSF in adjuvant treatment of operable breast cancer with 4 or more positive axillary nodes

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at